What is the optimal duration of immune checkpoint inhibitors in malignant tumors?Jiaxin Yin, Bicheng Zhang, Yuxiao Song et al.|Frontiers in Immunology|2022Cited by 36
The efficacy of immune checkpoint inhibitors is limited in elderly NSCLC: a retrospective efficacy study and meta-analysisJiaxin Yin, Bicheng Zhang, Yuxiao Song et al.|Aging|2023Cited by 14
Complement C1q induces the M2-polarization of tumor-associated macrophages in lung adenocarcinomaYuxiao Song, Bicheng Zhang, Jiaxin Yin et al.|Genes & Diseases|2023Cited by 11
NLRP12/C1qA positive feedback in tumor-associated macrophages regulates immunosuppression through LILRB4/NF-κB pathway in lung adenocarcinomaJiaxin Yin, Bicheng Zhang, Yuxiao Song et al.|Cancer Immunology Immunotherapy|2024Cited by 9
Increasing serum complement component 1q is associated with worse prognosis in advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a single-center, retrospective studyJiazhuo Tang, Bicheng Zhang, Fu Yang et al.|Journal of Thoracic Disease|2024Cited by 5